
POSTER PRESENTATIONS
01. Emerging concepts / New Agents
P01.01 - PLAP as Target for cancer immunotherapy - Development and Preclinical Characterization of Bispecific Monoclonal Antibody in Colorectal cancer immunotherapy
Norah Alrishedan, Oxford, United Kingdom
P01.02 - Selective induction of cell death in Jurkat cells with recombinant fungal lectin CNL
Milica Perisic Nanut, Ljubljana, Slovenia
P01.03 - RNAi mediated PD-1 knockdown induces a TCF-1 positive population in activated human CD8 T cells with stem-like associated marker profile
Anna Herbstritt, Munich, Germany
P01.04 - APEX-mediated biotinylation as a potent tool for evaluation of chemokine-receptor interactions and respective binding inhibitors
Antonia Beimert, Munich, Germany
P01.05 - Modelling T Cell migration in 3D vascular beds in a high-throughput microfluidic platform
Luuk de Haan, Oegstgeest, Netherlands
P01.06 - DSP216 blocks HLA-G and CD47 signaling toward immune cells and redesigns the immune suppressive tumor microenvironment
Lisa Jacob, Groningen, Netherlands
P01.07 - Galectin 9 dependent immune evasion machinery as a potential target for personalised immunotherapy of cancer
Vadim Sumbayev, Chatham Maritime, United Kingdom
02. Tumor microenvironment and microbiome in Immunotherapy
P02.01 - A bioinformatic analysis: the overexpression and clinical significance of HVEM in liver hepatocellular carcinoma
Kunmin Xiao, Beijing, China
P02.02 - Easy and scalable transfer of an immuno-oncology panel across a wide range of cancer tissue types
Pamela Pulimeno, Tolochenaz, Switzerland
P02.03 - Organization, function and gene expression of tertiary lymphoid structures in pancreatic cancer resembles lymphoid follicles in secondary lymphoid organs and their abundance is related to superior survival
Jonas Lehmann, Cologne, Germany
P02.04 - High-plex spatial immune cell profiling of the tumor microenvironment with ChipCytometry
Thomas Campbell, Saint Louis, United States
P02.05 - How proton pump inhibitors blunt immune checkpoint inhibitors efficacy: a role of the microbiome?
Eloïse Ramel, Bordeaux, France
P02.06 - Investigating the roles of IL-25 and ILC2s in APC-mutation-mediated colorectal cancer
Jane Murphy, Cambridge, United Kingdom
P02.07 - Innate immunity atlas of hepatocellular carcinoma unravels the differentiation hierarchy of myeloid NK cells and MDSCs
Domitille Chalopin, Bordeaux Cedex, France
P02.08 - The role of the inflammasome in the spatiotemporal evolution of the immune cell landscape in post-resection glioblastoma
Sébastian Lillo, Bordeaux, France
P02.09 - Integrated single-cell profiling dissects cell-state-specific enhancer landscapes of human tumor-infiltrating T cells
Christian Schmidl, Regensburg, Germany
03. Vaccine Therapy
P03.01 - Development of a multi-tumour antigen vaccine for hard-to-treat cancers
Carles Puig Saenz, Nottingham, United Kingdom
P03.02 - A mutated prostatic acid phosphatase (PAP) peptide-based vaccine induces PAP-specific CD8+ T cells with ex vivo cytotoxic capacities in HHDII/DR1 transgenic mice
Jubini Thomas, Nottingham, United Kingdom
P03.03 - Active immunization against human endogenous retrovirus type K (HERV-K) as an immunotherapeutic strategy against solid tumors
Peter Holst, COPENHAGEN, Denmark
P03.04 - Combined SCIB1 DNA vaccine and PD-1 checkpoint blockade for the treatment of intracranial tumours
Stephanie McArdle, Nottingham, United Kingdom
P03.05 - Vaccine immunotherapy against human endogenous retrovirus: a focus on anti-herv-k antibodies
Amaia V. Bermejo, Copenhagen, Denmark
P03.06 - Tumor associated antigens and pathogen antigens: friends or foes
Luigi Buonaguro, NAPOLI, Italy
P03.07 - Towards HERV-H Env protein based tumor stratification and intervention strategies
Jasmin Gille, Regensburg, Germany
P03.08 - Neoantigenic versus multi-antigenic personalized B16 melanoma vaccines comparison according to anti-tumor T cell response intensity
Ekaterina Ushakova, Moscow, Russian Federation
04. Precision Medicine Meets Immunotherapy (Immuno-Monitoring)
P04.01 - Volatile profiling using an eNose allows differentiation of volatile phases derived from serum, DC, or MLC culture supernatants from healthy or leukemic samples
Helga Schmetzer, Munich, Germany
P04.02 - A high sensitivity, tumor-informed liquid biopsy platform, designed to detect minimum residual disease at part per million resolution
Maik Pruess, Menlo Park, United States
P04.03 - Cancer Immunotherapies, Companion Diagnostics and Precision Medicine
Nora Cascante-Estepa, Bonn, Germany
05. Reverse translation
P05.01 - Platelets role in immunotherapy response in non-small cell lung cancer
Chiara Colarusso, Fisciano, Italy
06. Cell Therapy in Solid Tumors
P06.01 - ROR1-CAR T-cells as novel treatment strategy for anaplastic thyroid carcinoma
Dmitry Chernyakov, Halle (Saale), Germany
P06.02 - Anti-nucleolin CAR (chimeric antigen receptor)-T cell targeting Triple-Negative Breast Cancer - critical parameters in CAR-T cells generation
Teresa Abreu, Coimbra, Portugal
P06.03 - T cell mediated killing of neuroblastoma is inhibited by secreted MIF and MDK
Josephine Strijker, Utrecht, Netherlands
P06.04 - Immune responses against shared antigens are common in esophago-gastric cancer and can be enhanced using CD40-activated B cells
Martin Thelen, Cologne, Germany
07. Cell Therapy in Haematologic Diseases
P07.01 - THE POTENTIAL ROLE OF EXTRACELLULAR VESICLE-DERIVED SMALL RNAs IN AML RESEARCH AS NON-INVASIVE BIOMARKER
Lin Li, München, Germany
P07.02 - Control leukemia by inducing anti-cancer immune reactivity in vivo? - Potential of a DC-triggered mechanism
Helga Schmetzer, Munich, Germany
08. Combination Therapy
P08.01 - Combined approach of Adoptive Cell Therapy with Cytokine-Induced Killer cells retargeted with immunotools against HER-2-expressing breast cancer
Annavera Ventura, Padova, Italy
P08.02 - Liposomal doxorubicin enhances the radiation-induced abscopal effect by promoting the release of mitochondrial DNA
Liqun Wang, Freiburg im Breisgau, Germany
P08.03 - Interleukin-12 gene electrotransfer as an adjuvant immunotherapy to electrochemotherapy
Katja Ursic Valentinuzzi, Ljubljana, Slovenia
P08.04 - Phototherapy with cancer-specific nanoporphyrin potentiates immunotherapy in bladder cancer
Chong-xian Pan, Boston, United States
P08.05 - Lentiviral protein Vpx delivery systems as potential weapons to improve cytarabine treatment response against acute myeloid leukemia
Ramya Nair, Munich, Germany
P08.06 - Use of luciferase-labeled target cells to explore immune cell killing in high throughput format
Carla Castro, Freiburg, Germany
P08.07 - Identification of stress granule formation as a therapeutic target in chemotherapy treated colorectal cancer
Annalena Renner, Vienna, Austria
P08.08 - Immunomodulation by Lactate dehydrogenase C indicates a potential new opportunity for combination therapy
Adviti Naik, Doha, Qatar
P08.09 - Genome-wide CRISPR/Cas9 screening for identification of tumor-intrinsic mechanisms of resistance to anti-PD1 therapy in high-risk neuroblastoma
Divya Nagarajan, Uppsala, Sweden
P08.10 - Combining STING-agonist with radiotherapy remodels tumor immune microenvironment in human malignant pleural effusions
Rebecca Zirnbauer, Vienna, Austria
09. Young Researchers Session
P09.01 - Single-cell transcriptomic atlas-guided development of chimeric antigen-receptor (CAR) T cells for the treatment of acute myeloid leukemia
Adrian Gottschlich, Munich, Germany
P09.02 - Modular P329G-binding CAR T cells engineered to recognize human effector-silenced antibodies carrying a P329G Fc-mutation for targeting of solid tumor antigens
Sophia Stock, Munich, Germany
P09.03 - Activation of IL-22 signaling correlates with higher CD155 expression and stratifies poor outcomes of early-stage lung and breast cancer patients
Daria Briukhovetska, Munich, Germany
P09.04 - Cathepsin V inhibition prevents the activation of cystatin F and increases immune cell cytotoxicity
Emanuela Senjor, Ljubljana, Slovenia
P09.05 - Exploring the therapeutic vulnerabilities of cathepsin S hyperactive tumors
Johannes Hildebrand, München, Germany
P09.06 - A Toll-Like Receptor agonist represents a potential adjuvant in fourth generation CAR-T cell-based immunotherapy
Jolanda Magri, Candiolo, Italy
P09.07 - Deciphering the nature of the cooperation between monocytes/macrophages and CD8+ T cells during immunotherapy-induced tumor regression
Anaïs Vermare, Paris, France
P09.08 - The tumor immune microenvironment of head and neck cancer in relation to anatomical site classification
Tara Muijlwijk, Amsterdam, Netherlands
P09.09 - A CAR-T cell-based approach for the treatment of malignant T cell diseases
Maximilian Funk, Vienna, Austria
P09.10 - Dysregulated Expressions of Inhibitory Checkpoint Molecules and Their Ligands on T-Cells and Blasts in AML Relapses After Stem Cell Transplantation (SCT)
Sophia Bohlscheid, Munich, Germany
P09.11 - Anti-proliferative effects of gut microbial metabolites on human gastric adenocarcinoma cells and their potential synergy with dexamethasone
Deep Jyoti Bhuyan, Penrith, Australia
P09.12 - Hereditary homozygosity and allelic imbalance of HLA as common immune escape mechanisms in esophageal adenocarcinoma
Maria Garcia Marquez, Cologne, Germany
P09.13 - Immune geospatial profiling and characterization of glioma microenvironment after adoptive cell therapy shows differentially expressed antigen processing and cross-presentation gene signatures
Laura Falceto Font, Gainesville, United States
P09.14 - The role of IDO1 and cellular senescence in the efficacy of PD-1 pathway blockade and radiotherapy in aged mice with glioblastoma
Evridiki Asimakidou, Chicago, United States
P09.15 - Patient-derived head and neck tumor slice cultures - a versatile tool to study oncolytic virus action
Melissa Mayr, Innsbruck, Austria
P09.16 - MelARV vaccine with mutations in the immunosuppressive domain elicits increased immunity and elimination of established tumors in mice
Joana Daradoumis, Copenhagen, Denmark
P09.17 - High-resolution of neoantigen-specific T cell receptor activation patterns - moderate stimulation predicts sustained anti-tumor-response
Franziska Füchsl, München, Germany
P09.18 - TNF induction in essential for oncolytic influenza A virus induced cancer regression and tumor associated macrophage repolarization
Jakob Homola, Vienna, Austria
P09.19 - Complex primary organoid cultures to dissect immunogenic effects of therapy on macrophages in a precision medicine-like approach
Julijan Kabiljo, Wien, Austria
P09.20 - Impact of TCR independent, KIR-HLA-C interactions on KIR+CD8+ T cells in health and disease
Janine Kemming, Kongens Lyngby, Denmark
P09.21 - Modelling the spatial dynamics of oncolytic virotherapy in the presence of virus-resistant tumor cells
Darshak Bhatt, Groningen, Netherlands
P09.22 - Toward a rational design of immunonanotherapies
Vincent Mittelheisser, Strasbourg, France
P09.23 - Immune cell infiltration as a novel marker for predicting patient outcome in nephroblastoma
Lukas Watzke, Vienna, Austria